Process for isolation and radiolabeling of pharmaceuticals with isotopes of astatine

Patent · Tue Apr 07 00:00:00 EDT 1992

OSTI ID:5020967

Wilbur, D S; Hadley, S W

This patent describes a process for producing an At-211-labeled radiopharmaceutical compound. It comprises vaporizing At-211 from an irradiated bismuth metal target, and introducing the vaporized At-211 into a solution comprising a compound that binds the At-211 to form an At-211-labeled radiopharmaceutical compound.

• Assignee: NeoRx Corp., Seattle, WA (United States)
• Patent Number(s): US 5102651; A
• Application Number: PPN: US 7-459066
• OSTI ID: 5020967
• Resource Relation: Patent File Date: 29 Dec 1989
• Country of Publication: United States
• Language: English

Related Subjects

38 RADIATION CHEMISTRY, RADIOCHEMISTRY, AND NUCLEAR CHEMISTRY
37 INORGANIC
ORGANIC
PHYSICAL AND ANALYTICAL CHEMISTRY
LABELLED COMPOUNDS
SEPARATION PROCESSES
RADIOPHARMACEUTICALS
CHEMICAL PREPARATION
ASTATINE 211
ASTATINE ISOTOPES
BISMUTH
IRRADIATION
LABELLING
ALPHA DECAY RADIOISOTOPES
BETA DECAY RADIOISOTOPES
DRUGS
ELECTRON CAPTURE RADIOISOTOPES
ELEMENTS
HEAVY NUCLEI
HOURS LIVING RADIOISOTOPES
ISOTOPES
METALS
NUCLEI
ODD-EVEN NUCLEI
RADIOISOTOPES
SYNTHESIS
400703* - Radiochemistry & Nuclear Chemistry- Radioisotope Production
400202 - Isotope Effects
Isotope Exchange
& Isotope Separation